Hepatitis A vaccine
Brand names: Havrix, Avaxim, Vaqta
Hepatitis A vaccine is an inactivated vaccine used to provide active immunisation against hepatitis A virus infection, given to travellers to endemic areas and other at-risk groups.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It contains inactivated hepatitis A virus antigen that stimulates the immune system to produce protective antibodies, generating immunological memory against subsequent exposure.
Prescribing in practice
- It is contraindicated in those with a confirmed anaphylactic reaction to a previous dose or to a vaccine component, and acute febrile illness warrants deferral.
- Completion of the recommended schedule, including the later reinforcing dose, is needed for long-term protection.
- Administer by intramuscular injection and follow the relevant Green Book chapter, the SPC and current prescribing references for schedule and combined formulations.
Monitoring
Routine antibody monitoring is not generally required; observe after vaccination for immediate hypersensitivity and ensure the schedule is completed.
Counselling the patient
- A reinforcing dose is needed for lasting protection; keep a record of vaccination dates.
- Mild soreness at the injection site, headache or tiredness can occur and usually settle quickly.
- Continue food and water hygiene precautions when travelling, as no vaccine is fully protective.
Evidence & guidelines
Use of hepatitis A vaccine for travellers and other at-risk groups follows recommendations in the UK immunisation guidance (the Green Book).
Reference: UK Green Book; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Maddrey Discriminant Function (Alcoholic Hepatitis) · Alcoholic Liver Disease
- Lille Model (Steroid Response in Alcoholic Hepatitis) · Alcoholic Liver Disease
- FIB-4 Index · Liver Fibrosis
- Maddrey's Discriminant Function for Alcoholic Hepatitis · Hepatology
- Lille Model for Alcoholic Hepatitis · Hepatology
- AST to Platelet Ratio Index (APRI) · Hepatology
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023